Maria M. M. Santos
PhD (2004) in Chemistry (Organic Chemistry), Universidade Nova de Lisboa
Post- Doctoral Fellow, University of Barcelona and Universidade de Lisboa
Assistant Investigator, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Santos leads a research team of medicinal chemistry and the ultimate goal of her basic research is the development of general synthetic methods and strategies, and their application to the synthesis of bioactive molecules. Main achievements of Santos’s lab include the discovery of highly potent and selective MDM2-p53 interaction inhibitors, and novel indole-based scaffolds with antimalarial activity, as well as the development of heterocycles that act as NMDA receptor antagonists. She has also been involved in several research projects in collaboration with Hovione Pharmaceutical, including the optimization of synthetic process to obtain APIs.
Nunes RC, Ribeiro CJA, Monteiro A, Rodrigues CMP, Amaral JD, Santos MMM. In vitro targeting of colon cancer cells using spiropyrazoline oxindoles. Eur J Med Chem 2017; 20: 168-179
Espadinha M, Dourado J, Lajarin-Cuesta R, Herrera-Arozamena C, Gonçalves L, Rodríguez-Franco MI, de los Rios C, Santos MMM. Optimization of bicyclic lactam derivatives as NMDA receptor antagonists. Chem Med Chem 2017; 12: 537-45.
Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L. DIMP53-1: A novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Molecular Oncology 2017; 11: 612-27.
Pereira NAL, Monteiro A, Machado M, Gut J, Molins E, Perry MJ, Dourado J, Moreira R, Rosenthal PJ, Prudêncio M, Santos MMM. Enantiopure Indolizinoindolones with In Vitro Efficiency against Blood- and Liver-Stage Malaria Parasites. Chem Med Chem 2015; 10: 2080-89.
Lourenço NT, Sobral L, Antunes R, Santos MMM, Espadinha M. Process for the preparation of Umeclidinium bromide. Hovione PharmaScience, Patent request INPI nº 109740, 2016/11/14.